Bellevue Group AG Has $1.37 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Bellevue Group AG reduced its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 15.7% in the third quarter, HoldingsChannel reports. The firm owned 11,981 shares of the company’s stock after selling 2,229 shares during the period. Bellevue Group AG’s holdings in Vaxcyte were worth $1,369,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Riverview Trust Co bought a new stake in shares of Vaxcyte in the 3rd quarter valued at $27,000. Fifth Third Bancorp bought a new position in Vaxcyte during the second quarter worth $35,000. Blue Trust Inc. grew its holdings in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after purchasing an additional 93 shares during the period. J.Safra Asset Management Corp increased its stake in Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after purchasing an additional 526 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in shares of Vaxcyte during the second quarter valued at about $70,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Trading Up 0.4 %

Shares of Vaxcyte stock opened at $94.34 on Friday. The stock has a fifty day simple moving average of $105.60 and a 200 day simple moving average of $90.35. Vaxcyte, Inc. has a 12-month low of $50.04 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter in the prior year, the business posted ($0.91) earnings per share. On average, research analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on PCVX. Mizuho raised their target price on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Needham & Company LLC restated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, November 6th. BTIG Research upped their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group lifted their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte presently has an average rating of “Buy” and a consensus price target of $147.50.

Insiders Place Their Bets

In other Vaxcyte news, CEO Grant Pickering sold 2,366 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total value of $245,803.74. Following the completion of the transaction, the chief executive officer now owns 137,398 shares in the company, valued at $14,274,278.22. This represents a 1.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $106.80, for a total value of $854,400.00. Following the sale, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at approximately $21,968,226. This represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 102,464 shares of company stock valued at $11,455,576. Corporate insiders own 3.10% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.